MedTrace Logo

Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study).

NCT03917199 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2019-09-17

No results posted yet for this study

Summary

The ULYSSES study is a single-center, prospective study aimed at evaluation of myocardial ischemia using regadenoson low-dose dynamic computed tomography myocardial perfusion imaging (CTP) in patients diagnosed with intermediate coronary artery stenoses in referrence to the magnetic resonance myocardial perfusion imaging (MR MPI).

Conditions

Sponsors & Collaborators

  • National Science Centre, Poland

    collaborator OTHER_GOV

  • National Institute of Cardiology, Warsaw, Poland

    lead OTHER

Principal Investigators

  • Cezary Kepka, MD, PhD · Institute of Cardiology, warsaw, PL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-07-31
Completion
2019-07-11

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03917199 on ClinicalTrials.gov